Company profile
Burzynski Research Institute, Inc.
OTC: BZYR · Healthcare · Medical - Pharmaceuticals
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ 54GM —SS 41
v0.1 · 25/100 weight · pillars only
↑ listing tenure, disclosure history · ↓ workforce scale, return on assets
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$1.4M
Employees
1
as of 2026-08-26
Market cap
$1.1M
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$1.4M-$1.4M2025
Operating income-$1.4M-$1.4M2025
Total assets$847$8472025
Liabilities$42.5k$42.5k2025
Equity-$41.6k-$41.6k2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Burzynski Research Institute, Inc.’s revenue?
Burzynski Research Institute, Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Anything Technologies Media, Inc.32DOncology Pharma Inc.——Aethlon Medical, Inc.42DThe Cannaisseur Group, Inc.8DOdyssey Health, Inc.21DAvalon GloboCare Corp.35DNeighbors
Harris →Key facts
CEOStanislaw R. Burzynski
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersHouston, TX
ExchangeOTC: BZYR
Employees1
IPO date1997-01-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.